Pith. sign in

REVIEW 2 major objections 2 minor 68 references

Data-Driven Analysis of AI in Medical Device Software in China: Trends of Deep Learning and Traditional AI Based on Regulatory Data

T0 review · 2 major / 2 minor · reviewed 2026-05-23 · grok-4.3

Challenge this review Download PDF Read on arXiv ↗

Pith's one-line read Automated screening of China's medical device registry identifies 43 AI-enabled devices and maps their use by specialty.

desk verdict The paper reports 43 AI-enabled devices from China's NMPA but the classification rules lack any validation. read the letter →

arxiv 2411.07378 v3 submitted 2024-11-11 cs.AI

Yu Han , Aaron Ceross , Sarim Ather , Jeroen H.M. Bergmann This is my paper
classification cs.AI
keywords AImedicaldevicesdevicesoftwareregulatorydatabaseChinadata-drivenanalysisdeeplearningNMPAautomatedextraction
verification ladder T0 review T1 audit T2 compute T3 formal

The pith

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The reading

The paper applies automated extraction rules to more than four million entries in the National Medical Products Administration database to isolate medical device software registrations and then flag those that incorporate artificial intelligence. It reports 2,174 total MDSW registrations and determines that 43 of them are AI-enabled, with the highest shares appearing in respiratory, ophthalmology/endocrinology, and orthopedics applications. A sympathetic reader would care because the method converts an otherwise intractable volume of regulatory filings into a repeatable snapshot of where AI is entering clinical devices. The work positions large public databases as a source of ongoing, low-cost insight into AI adoption rather than one-off manual audits.

What carries the argument

Automated extraction rules applied to the NMPA regulatory database that classify entries as AI-enabled medical device software without manual review of each record.

What would settle it

A manual audit of a random sample of the 2,174 MDSW entries that finds more than a small percentage of misclassified AI versus non-AI cases.

Watch

Extended reading notes

Core claim

By processing more than 4 million database entries, the study identifies 2,174 medical device software registrations, including 531 standalone and 1,643 integrated within devices, and classifies 43 of these as AI-enabled. The leading medical specialties are respiratory (20.5 percent), ophthalmology/endocrinology (12.8 percent), and orthopedics (10.3 percent). The same automated pipeline is presented as a scalable way to generate reproducible, updatable views of AI in regulated medical technology.

Load-bearing premise

The automated rules correctly and exhaustively separate AI-enabled entries from all others with no significant false positives or missed cases.

Editorial extensions

If this is right

  • The distribution of AI use across specialties can be tracked and updated whenever new registrations enter the database.
  • The same extraction rules can be reapplied to compare trends between traditional AI and deep-learning approaches over time.
  • Regulators and manufacturers gain a baseline count and specialty map that can be refreshed without repeating the full manual screening effort.
  • The speed of insight generation increases because the method replaces exhaustive manual review with rule-based filtering.

Reading between the lines

Editorial extensions of the paper, not claims the author makes directly.

  • The same rule-based filtering could be tested on regulatory databases maintained by other national authorities to produce comparable adoption statistics.
  • If the classification rules are later refined or supplemented with human review, the reported count of 43 AI-enabled devices and the specialty percentages could shift.
  • The approach suggests that public regulatory data alone can serve as a monitoring tool for the diffusion of AI into specific clinical areas.
Share X Bluesky LinkedIn Reddit HN

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, simulated authors' rebuttal, and a circularity audit.

Referee Report

2 major / 2 minor

Summary. The paper claims to perform the first extensive data-driven analysis of AI-enabled medical device software (AIMD) in China by automatically screening >4 million NMPA regulatory entries, identifying 2,174 MDSW registrations (531 standalone, 1,643 integrated) of which 43 are AI-enabled, and reporting specialty distributions (respiratory 20.5%, ophthalmology/endocrinology 12.8%, orthopedics 10.3%). It positions the automated extraction as a scalable, reproducible method for regulatory data analysis.

Significance. If the classification step is shown to be accurate and exhaustive, the work would demonstrate a practical, updatable pipeline for mining large regulatory databases to track AI adoption in medical devices, filling a gap in China-specific AIMD statistics and illustrating the value of automation for regulatory informatics.

major comments (2)
  1. [Abstract / Methods] Abstract and Methods (implied extraction procedure): The headline result of 43 AIMD devices is obtained via unspecified automated rules applied to >4M entries, yet the manuscript supplies neither the explicit rule set, a validation set, inter-rater agreement statistics, nor precision/recall estimates for the AI-enabled classification. Without these, false positives or missed cases directly undermine the reported specialty breakdowns and the claim of a reproducible data-driven analysis.
  2. [Results] Results section (specialty percentages): The percentages (e.g., respiratory 20.5%) are presented as direct outputs of the unvalidated classifier; any systematic misclassification would propagate to these figures and to the assertion that the study provides the first extensive exploration of AIMD in China.
minor comments (2)
  1. [Abstract] Abstract: The phrase 'This approach greatly improves the speed of data extracting' is stated without any quantitative benchmark against manual screening or prior studies.
  2. [Abstract] Abstract: The claim of being the 'first extensive, data-driven exploration' would benefit from explicit comparison to any earlier Chinese regulatory analyses of medical-device AI.

Simulated Author's Rebuttal

2 responses · 0 unresolved

We thank the referee for their detailed review and constructive suggestions. We address the major comments below and have revised the manuscript accordingly to improve transparency and reproducibility.

read point-by-point responses

  1. Referee: [Abstract / Methods] Abstract and Methods (implied extraction procedure): The headline result of 43 AIMD devices is obtained via unspecified automated rules applied to >4M entries, yet the manuscript supplies neither the explicit rule set, a validation set, inter-rater agreement statistics, nor precision/recall estimates for the AI-enabled classification. Without these, false positives or missed cases directly undermine the reported specialty breakdowns and the claim of a reproducible data-driven analysis.

    Authors: We agree that the Methods section should provide more explicit details on the automated rules to enhance reproducibility. In the revised manuscript, we will add a dedicated subsection describing the keyword-based screening criteria used to identify AI-enabled devices from the regulatory entries. Regarding validation, we acknowledge that no formal validation set or inter-rater agreement statistics were included, as the approach relied on deterministic keyword matching rather than machine learning classification. We will include a limitations section discussing the potential for false positives/negatives and the trade-offs of scalability versus exhaustive manual review. This addresses the concern while preserving the data-driven, large-scale nature of the analysis. revision: yes

  2. Referee: [Results] Results section (specialty percentages): The percentages (e.g., respiratory 20.5%) are presented as direct outputs of the unvalidated classifier; any systematic misclassification would propagate to these figures and to the assertion that the study provides the first extensive exploration of AIMD in China.

    Authors: The specialty distributions are indeed based on the identified set of 43 devices. With the addition of the explicit rules and limitations discussion in the revised manuscript, readers will be better positioned to assess the robustness of these percentages. We maintain that the study provides the first extensive data-driven exploration at this scale, as no prior work has automatically screened over 4 million NMPA entries for AIMD. We will clarify in the text that the figures are subject to the classification method's limitations. revision: partial

Circularity Check

0 steps flagged · score 0.0 of 10

No circularity: direct database counts with no derivation or fitted model

full rationale

The paper reports counts and specialty breakdowns obtained by applying classification rules to an external regulatory database (>4M entries screened for 2,174 MDSW and 43 AIMD). No equations, parameters, predictions, or self-citations appear in the derivation chain. The result is a direct enumeration from external data rather than any internal loop that reduces outputs to inputs by construction. The absence of validation for the rules is a reproducibility concern but does not constitute circularity under the defined patterns.

Assumptions & free parameters 0 free parameters · 1 assumptions · 0 invented entities

The analysis rests on the assumption that the NMPA database is both complete and accurately labeled for AI content; no free parameters or new entities are introduced.

assumptions (1)
  • domain assumption The NMPA regulatory database contains accurate and complete records of all registered medical device software, including correct AI labeling.
    All counts and percentages derive directly from querying this single external source without independent verification.

how reviews work

0 comments
Cite this review

Pith. "Pith review of Data-Driven Analysis of AI in Medical Device Software in China: Trends of Deep Learning and Traditional AI Based on Regulatory Data." pith.science (2026). https://pith.science/paper/2411.07378

@misc{pith2026241107378,
  author       = {Pith},
  title        = {Pith review of: Data-Driven Analysis of AI in Medical Device Software in China: Trends of Deep Learning and Traditional AI Based on Regulatory Data},
  year         = {2026},
  howpublished = {\url{https://pith.science/paper/2411.07378}},
  note         = {Machine review of arXiv:2411.07378}
}
read the original abstract

Artificial intelligence (AI) in medical device software (MDSW) represents a transformative clinical technology, attracting increasing attention within both the medical community and the regulators. In this study, we leverage a data-driven approach to automatically extract and analyze AI-enabled medical devices (AIMD) from the National Medical Products Administration (NMPA) regulatory database. The continued increase in publicly available regulatory data requires scalable methods for analysis. Automation of regulatory information screening is essential to create reproducible insights that can be quickly updated in an ever changing medical device landscape. More than 4 million entries were assessed, identifying 2,174 MDSW registrations, including 531 standalone applications and 1,643 integrated within medical devices, of which 43 were AI-enabled. It was shown that the leading medical specialties utilizing AIMD include respiratory (20.5%), ophthalmology/endocrinology (12.8%), and orthopedics (10.3%). This approach greatly improves the speed of data extracting providing a greater ability to compare and contrast. This study provides the first extensive, data-driven exploration of AIMD in China, showcasing the potential of automated regulatory data analysis in understanding and advancing the landscape of AI in medical technology.

Figures

Figures reproduced from arXiv: 2411.07378 by the authors.

Figure 1
Figure 1. Medical device registration pathways set out by the NMPA. Imported and domestic [PITH_FULL_IMAGE:figures/full_fig_p003_1.png] view at source ↗
Figure 2
Figure 2. UDI code layout according to YY/T 1630-2018. [PITH_FULL_IMAGE:figures/full_fig_p004_2.png] view at source ↗
Figure 3
Figure 3. Pseudocode for MDSW and AIMD Identification Process [PITH_FULL_IMAGE:figures/full_fig_p006_3.png] view at source ↗
Figures from the paper (5 more)
Figure 4
Figure 4. Figure 4: Flowchart for the selection process for the identification of software and AIMD [PITH_FULL_IMAGE:figures/full_fig_p007_4.png]
Figure 5
Figure 5. Figure 5: Domestic and Imported SaMD & SiMD Devices: AI vs. Non-AI Distribution. Different [PITH_FULL_IMAGE:figures/full_fig_p008_5.png]
Figure 6
Figure 6. Figure 6: A geographic map of non-foreign medical device software are registration 2020–2024 ( [PITH_FULL_IMAGE:figures/full_fig_p009_6.png]
Figure 7
Figure 7. Figure 7: An alluvial diagram illustrating the types of 43 AI medical devices and the risk 13 [PITH_FULL_IMAGE:figures/full_fig_p013_7.png]
Figure 8
Figure 8. Figure 8: Distribution of AIMD on different medical specialty and algorithm [PITH_FULL_IMAGE:figures/full_fig_p014_8.png]

Discussion (0). Sign in to comment.

Reference graph

Works this paper leans on

68 extracted references · 68 canonical work pages

  1. [1]

    Notice of the state council on the new generation artificial intelligence plan,

    State Council of the People’s Republic of China, “Notice of the state council on the new generation artificial intelligence plan,” 2017. [Online]. Available: http: //www.gov.cn/zhengce/content/2017-07/20/content_5211996.htm

    work page 2017

  2. [2]

    W. M. Morrison,China’s economic rise: history, trends, challenges, and implications for the United States. Congressional Research Service Washington, DC, 2013

    work page 2013

  3. [3]

    China population in 2022

    worldometer, “China population in 2022.” [Online]. Available: https://www.worldometers. info/world-population/china-population/

    work page 2022

  4. [4]

    Chinese medical device industry: How to thrive in an increasingly competitive market?

    Deloitte, “Chinese medical device industry: How to thrive in an increasingly competitive market?” 2021. [Online]. Available: https://www2.deloitte.com/cn/en/pages/ life-sciences-and-healthcare/articles/chinese-medical-device-industry-whitepaper.html

    work page 2021

  5. [5]

    The practical implementation of artificial intelligence technologies in medicine,

    J. He, S. L. Baxter, J. Xu, J. Xu, X. Zhou, and K. Zhang, “The practical implementation of artificial intelligence technologies in medicine,”Nature Medicine, vol. 25, no. 1, pp. 30–36, 2019

    work page 2019

  6. [6]

    Regulatory frameworks for ai-enabled medical device software in china: Comparative analysis and review of implications for global manufactur- ers,

    Y. Han, A. Ceross, and J. Bergmann, “Regulatory frameworks for ai-enabled medical device software in china: Comparative analysis and review of implications for global manufactur- ers,”JMIR AI, vol. 3, p. e46871, 2024

    work page 2024

  7. [7]

    Announcement of the nmpa on issuing the guiding principles for technical review of medical device software registration

    NMPA, “Announcement of the nmpa on issuing the guiding principles for technical review of medical device software registration.” [Online]. Available: https://www.nmpa.gov.cn/ ylqx/ylqxggtg/ylqxqtgg/20150805120001562.html?type=pc&m= 23

    work page arXiv

  8. [8]

    Key points of deep learning decision-assisting medical device software review

    Artificial Intelligence Medical Device Innovation and Cooperation Platform, “Key points of deep learning decision-assisting medical device software review.” [Online]. Available: http://aimd.org.cn/newsinfo/1339997.html?templateId=506998

    work page arXiv

Show all 68 references
  1. [9]

    Announcement of nmpa on issuing the guiding principles for the classification and definition of artificial intelligence medical software products (no. 47 of 2021),

    National Medical Products Administration, “Announcement of nmpa on issuing the guiding principles for the classification and definition of artificial intelligence medical software products (no. 47 of 2021),” 2021. [Online]. Available: https: //www.nmpa.gov.cn/xxgk/ggtg/qtggtg/...

    2021

  2. [10]

    9).” [Online]

    CCFDIE, “Announcement of the center for device evaluation of the state food and drug administration on the release of the guidelines for the registration and review of medical device software (2022 revision) (2022 no. 9).” [Online]. Available: https://www.ccfdie.org/cn/yjxx/yl...

    2022

  3. [11]

    Notice of the center for device evaluation of the nmpa on issuing the guiding principles for the registration review of artificial intelligence medical devices (no. 8, 2022)

    CIRS, “Notice of the center for device evaluation of the nmpa on issuing the guiding principles for the registration review of artificial intelligence medical devices (no. 8, 2022).” [Online]. Available: https://www.cirs-group.com/cn/md/ gjyjjqszxgyfbrgznylqxzcsczdyzdtg-2022nd8h

    2022

  4. [12]

    Chestx-ray8: Hospital- scale chest x-ray database and benchmarks on weakly-supervised classification and local- ization of common thorax diseases,

    X. Wang, Y. Peng, L. Lu, Z. Lu, M. Bagheri, and R. M. Summers, “Chestx-ray8: Hospital- scale chest x-ray database and benchmarks on weakly-supervised classification and local- ization of common thorax diseases,” inIEEE Conference on Computer Vision and Pattern Recognition (CVP...

    2017

  5. [13]

    Enhancing next-generation sequencing- guided cancer care through cognitive computing,

    N. M. Patel, V. V. Michelini, J. M. Snell, S. Balu, A. P. Hoyle, J. S. Parker, M. C. Hayward, D. A. Eberhard, A. H. Salazar, P. McNeillieet al., “Enhancing next-generation sequencing- guided cancer care through cognitive computing,”The Oncologist, vol. 23, no. 2, p. 179, 2018

    2018

  6. [14]

    Artificial intelligence and deep learning in ophthalmology,

    D. S. W. Ting, L. R. Pasquale, L. Peng, J. P. Campbell, A. Y. Lee, R. Raman, G. S. W. Tan, L. Schmetterer, P. A. Keane, and T. Y. Wong, “Artificial intelligence and deep learning in ophthalmology,”British Journal of Ophthalmology, vol. 103, no. 2, pp. 167–175, 2019

    2019

  7. [15]

    Szolovits,Artificial intelligence in medicine

    P. Szolovits,Artificial intelligence in medicine. Routledge, 2019

    2019

  8. [16]

    Use of artificial intelligence to improve diabetes outcomes in patients using multiple daily injections therapy,

    G. P. Forlenza, “Use of artificial intelligence to improve diabetes outcomes in patients using multiple daily injections therapy,”Diabetes Technology & Therapeutics, vol. 21, no. S2, pp. S2–4, 2019

    2019

  9. [17]

    Can ai technologies close the diagnostic gap in tu- berculosis?

    C. Tzelios and R. R. Nathavitharana, “Can ai technologies close the diagnostic gap in tu- berculosis?”The Lancet Digital Health, vol. 3, no. 9, pp. e535–e536, 2021

    2021

  10. [18]

    Tuberculosis detection from chest x-rays for triaging in a high tuberculosis- burden setting: an evaluation of five artificial intelligence algorithms,

    Z. Z. Qin, S. Ahmed, M. S. Sarker, K. Paul, A. S. S. Adel, T. Naheyan, R. Barrett, S. Banu, and J. Creswell, “Tuberculosis detection from chest x-rays for triaging in a high tuberculosis- burden setting: an evaluation of five artificial intelligence algorithms,”The Lancet Digi...

    2021

  11. [19]

    Pivotal trial of an autonomous ai-based diagnostic system for detection of diabetic retinopathy in primary care offices,

    M. D. Abràmoff, P. T. Lavin, M. Birch, N. Shah, and J. C. Folk, “Pivotal trial of an autonomous ai-based diagnostic system for detection of diabetic retinopathy in primary care offices,”NPJ Digital Medicine, vol. 1, no. 1, pp. 1–8, 2018. 24

    2018

  12. [20]

    Regulatory responses and approval status of artificial intel- ligence medical devices with a focus on china,

    Y. Liu, W. Yu, and T. Dillon, “Regulatory responses and approval status of artificial intel- ligence medical devices with a focus on china,”npj Digital Medicine, vol. 7, no. 1, p. 255, 2024

    2024

  13. [21]

    Announcement of the state food and drug administration on publishing the special review procedures for innovative medical devices (2018 no. 83)

    NMPA, “Announcement of the state food and drug administration on publishing the special review procedures for innovative medical devices (2018 no. 83).” [Online]. Available: https: //www.nmpa.gov.cn/zhuanti/cxylqx/cxylqxzyxx/20181105160001106.html?type=pc&m=

    2018

  14. [22]

    Announcement of the general administration on publishing the priority review and approval procedures for medical devices (no. 168, 2016)

    ——, “Announcement of the general administration on publishing the priority review and approval procedures for medical devices (no. 168, 2016).” [Online]. Available: https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20161026164001187.html

    2016

  15. [23]

    Announcement of the state food and drug administration on issuing the

    ——, “Announcement of the state food and drug administration on issuing the "emergency approval procedures for medical devices" (2021 no. 157).” [Online]. Available: https://www.nmpa.gov.cn/ylqx/ylqxggtg/20211230171343118.html?type=pc&m=

    2021

  16. [24]

    Imdrf interpretation of personalized medical device terms,

    M. Yue, Z. Wenwen, P. Shuo, H. Yiwu, L. Bin, and L. Zhong, “Imdrf interpretation of personalized medical device terms,”China Pharmaceutical Affairs, vol. 33, no. 1, pp. 41–44, 2019

    2019

  17. [25]

    Pilot project plan for udi system for medical devices (no.56, 2019)

    NMPA, “Pilot project plan for udi system for medical devices (no.56, 2019).” [Online]. Available: https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/fgwj/gzwj/ gzwjylqx/20190703175301499.html

    2019

  18. [26]

    Rules for unique device identification system (no. 66, 2019)

    ——, “Rules for unique device identification system (no. 66, 2019).” [Online]. Available: https://www.nmpa.gov.cn/ylqx/ylqxggtg/ylqxqtgg/20190827092601750.html

    2019

  19. [27]

    Medical device udi database,

    N. M. P. Administration, “Medical device udi database,” https://udi.nmpa.gov.cn/

  20. [28]

    Yy/t 1630-2018

    NMPA, “Yy/t 1630-2018.” [Online]. Available: https://udi.nmpa.gov.cn/toDetail.html? infoId=66&CatalogId=2

    2018

  21. [29]

    Software as a medical device

    Food and Drug Administration, “Software as a medical device.” [On- line]. Available: https://www.fda.gov/medical-devices/digital-health-center-excellence/ software-medical-device-samd

  22. [30]

    Software as a Medical Device (SaMD): Key Definitions,

    International Medical Device Regulators Forum (IMDRF), “Software as a Medical Device (SaMD): Key Definitions,” 2013, accessed: 2024-02-01. [Online]. Available: https://www.imdrf.org/documents/software-medical-device-samd-key-definitions

    2013

  23. [31]

    Medical device catalog

    NMPA, “Medical device catalog.” [Online]. Available: https://www.nmpa.gov.cn/wwwroot/ gyx02302/flml.htm

  24. [32]

    Announcement of nmpa issuing the guidelines for the classification and definition of artificial intelligence medical software products,

    National Medical Products Administration, “Announcement of nmpa issuing the guidelines for the classification and definition of artificial intelligence medical software products,” 2021. [Online]. Available: https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/ 20210708111147171.html?type=pc&m=

    2021

  25. [33]

    Udi dataset reference

    ——, “Udi dataset reference.” [Online]. Available: https://udi.nmpa.gov.cn

  26. [34]

    Unique Device Identifier database,

    The National Medical Products Administration, “Unique Device Identifier database,” 2023. [Online]. Available: https://udi.nmpa.gov.cn/ 25

    2023

  27. [35]

    Medical Equipment

    "Medical Equipment" Magazine Issue 15, 2022, “Review points of artificial intelligence software for ct imaging.” [Online]. Available: https://www.ylzbzz.org.cn/index.php?m= content&c=index&a=show&catid=43&id=152

    2022

  28. [36]

    Medical specialties,

    J. M. Torpy, A. E. Burke, and R. M. Glass, “Medical specialties,”JAMA, vol. 298, no. 9, pp. 1120–1120, 2007

    2007

  29. [37]

    The emergence of medical specialization in the nineteenth century,

    G. Weisz, “The emergence of medical specialization in the nineteenth century,”Bulletin of the History of Medicine, vol. 77, no. 3, pp. 536–574, 2003

    2003

  30. [38]

    Impact of ultra-high-resolution imaging of the lungs on per- ceived diagnostic image quality using photon-counting ct,

    V. Van Ballaer, A. Dubbeldam, E. Muscogiuri, L. Cockmartin, H. Bosmans, W. Coudyzer, J. Coolen, and W. de Wever, “Impact of ultra-high-resolution imaging of the lungs on per- ceived diagnostic image quality using photon-counting ct,”European Radiology, vol. 34, no. 3, pp. 1895...

    1904

  31. [39]

    Imaging tech- niques in veterinary medicine. part ii: Computed tomography, magnetic resonance imaging, nuclear medicine,

    A. Greco, L. Meomartino, G. Gnudi, A. Brunetti, and M. Di Giancamillo, “Imaging tech- niques in veterinary medicine. part ii: Computed tomography, magnetic resonance imaging, nuclear medicine,”European Journal of Radiology Open, vol. 10, p. 100467, 2023

    2023

  32. [40]

    Dinesh, A

    P. Dinesh, A. Vickram, and P. Kalyanasundaram, “Medical image prediction for diagnosis of breast cancer disease comparing the machine learning algorithms: Svm, knn, logistic regres- sion, random forest and decision tree to measure accuracy,” inAIP Conference Proceedings, vol. ...

    2024

  33. [41]

    Academic Press, 2023

    S.K.Zhou, H.Greenspan, andD.Shen, Deep learning for medical image analysis. Academic Press, 2023

    2023

  34. [42]

    Rules for the naming of generic names of medical devices,

    C. Food and D. Administration, “Rules for the naming of generic names of medical devices,” Order No. 19 of the China Food and Drug Administration, 2015, accessed on [insert date of access]. [Online]. Available: https://www.nmpa.gov.cn/ylqx/ylqxfgwj/ylqxbmgzh/ 20151221120001127.html

    2015

  35. [43]

    The state of artificial intelligence-based fda- approved medical devices and algorithms: an online database,

    S. Benjamens, P. Dhunnoo, and B. Meskó, “The state of artificial intelligence-based fda- approved medical devices and algorithms: an online database,”NPJ digital medicine, vol. 3, no. 1, p. 118, 2020

    2020

  36. [44]

    On the analyses of medical images using traditional machine learning techniques and convolutional neural networks,

    S. Iqbal, A. N. Qureshi, J. Li, and T. Mahmood, “On the analyses of medical images using traditional machine learning techniques and convolutional neural networks,”Archives of Computational Methods in Engineering, vol. 30, no. 5, pp. 3173–3233, 2023

    2023

  37. [45]

    A review of deep learning techniques for lung cancer screening and diagnosis based on ct images,

    M. A. Thanoon, M. A. Zulkifley, M. A. A. Mohd Zainuri, and S. R. Abdani, “A review of deep learning techniques for lung cancer screening and diagnosis based on ct images,” Diagnostics, vol. 13, no. 16, p. 2617, 2023

    2023

  38. [46]

    Application of artificial intelligence to imaging interpretations in the musculoskeletal area: Where are we? where are we going?

    V. Bousson, N. Benoist, P. Guetat, G. Attané, C. Salvat, and L. Perronne, “Application of artificial intelligence to imaging interpretations in the musculoskeletal area: Where are we? where are we going?”Joint Bone Spine, vol. 90, no. 1, p. 105493, 2023

    2023

  39. [47]

    Deep learning for neurodegenerative disorder (2016 to 2022): A systematic review,

    J. Chaki and M. Woźniak, “Deep learning for neurodegenerative disorder (2016 to 2022): A systematic review,”Biomedical Signal Processing and Control, vol. 80, p. 104223, 2023. 26

    2016

  40. [48]

    Artificial intelligence and deep learning: New tools for histopathological diagnosis of nonalcoholic fatty liver dis- ease/nonalcoholic steatohepatitis,

    Y. Takahashi, E. Dungubat, H. Kusano, and T. Fukusato, “Artificial intelligence and deep learning: New tools for histopathological diagnosis of nonalcoholic fatty liver dis- ease/nonalcoholic steatohepatitis,”Computational and Structural Biotechnology Journal, vol. 21, pp. 249...

    2023

  41. [49]

    Artificial intelligence applications in hepatology,

    J. M. Schattenberg, N. Chalasani, and N. Alkhouri, “Artificial intelligence applications in hepatology,”Clinical Gastroenterology and Hepatology, vol. 21, no. 8, pp. 2015–2025, 2023

    2015

  42. [50]

    Thyroid stimulating hormone and thyroid hormones (triiodothy- ronine and thyroxine): an american thyroid association-commissioned review of current clinical and laboratory status,

    K. Van Uytfanghe, J. Ehrenkranz, D. Halsall, K. Hoff, T. P. Loh, C. A. Spencer, J. Köhrle, and A. T. F. T. W. Group, “Thyroid stimulating hormone and thyroid hormones (triiodothy- ronine and thyroxine): an american thyroid association-commissioned review of current clinical an...

    2023

  43. [51]

    Medical image processing and radiotherapy planning software for seed implantation medical imaging software (national20153701878)

    Daohoo, “Medical image processing and radiotherapy planning software for seed implantation medical imaging software (national20153701878).” [Online]. Available: https://www.daohoogroup.com/zhuceshuju/804.html

  44. [52]

    Medical imaging system

    FDA 510(k) database, “Medical imaging system.” [Online]. Available: https://www. accessdata.fda.gov/scripts/cdrh/cfdocs/cfpcd/classification.cfm?id=5630

  45. [53]

    (2024) ‘time is brain’: Aidoc releases complete ai package to speed identification and treatment of stroke

    Aidoc. (2024) ‘time is brain’: Aidoc releases complete ai package to speed identification and treatment of stroke. Accessed: 2024-XX-XX. [Online]. Available: https://www.aidoc.com/about/news/aidoc-stroke-package/

    2024

  46. [54]

    Fda approves marketing of clinical decision sup- port software for stroke triage in midst of renewed focus on digital health applications,

    S. P. Boggs, “Fda approves marketing of clinical decision sup- port software for stroke triage in midst of renewed focus on digital health applications,” 2018, accessed: 2024-XX-XX. [Online]. Available: https://www.squirepattonboggs.com/~/media/files/insights/publications/2018...

    2018

  47. [55]

    Zebra medical vision ltd. - 510(k) premarket notification,

    U.S. Food and Drug Administration (FDA), “Zebra medical vision ltd. - 510(k) premarket notification,” 2020, accessed: 2024-XX-XX. [Online]. Available: https: //www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K200905

    2020

  48. [56]

    Heartflow to present latest data on ai-enabled coro- nary artery disease management at tct 2024,

    HeartFlow, “Heartflow to present latest data on ai-enabled coro- nary artery disease management at tct 2024,” 2024, ac- cessed: 2024-XX-XX. [Online]. Available: https://www.heartflow.com/newsroom/ heartflow-to-present-latest-on-ai-enabled-coronary-artery-disease-management/

    2024

  49. [57]

    Aice deep learning reconstruction,

    Canon Medical Systems, “Aice deep learning reconstruction,” 2024, accessed: February 1, 2025. [Online]. Available: https://anz.medical.canon/products/computed-tomography/ aice_dlr

    2024

  50. [58]

    Air recon dl - magnetic resonance imaging,

    GE Healthcare, “Air recon dl - magnetic resonance imaging,” 2024, accessed: February 1, 2025. [Online]. Available: https://www.gehealthcare.com/products/ magnetic-resonance-imaging/air-recon-dl

    2024

  51. [59]

    Vivid ultrasound systems,

    ——, “Vivid ultrasound systems,” 2024, accessed: February 1, 2025. [Online]. Available: https://www.gehealthcare.com.au/products/ultrasound/vivid 27

    2024

  52. [60]

    Acumen hypotension prediction index (hpi),

    Edwards Lifesciences, “Acumen hypotension prediction index (hpi),” 2024, accessed: February 1, 2025. [Online]. Available: https://www.edwards.com/healthcare-professionals/ products-services/predictive-monitoring/hpi

    2024

  53. [61]

    Diabetic retinopathy fundus image-assisted diagnosis software re- port 2024, global revenue, key companies market share & rank,

    QY Research, “Diabetic retinopathy fundus image-assisted diagnosis software re- port 2024, global revenue, key companies market share & rank,” 2024, ac- cessed: 2024-10-07. [Online]. Available: https://cn.qyresearch.com/reports/3318113/ diabetic-retinopathy-fundus-image-assist...

    2024

  54. [62]

    Approval of artificial intelligence and machine learning-based medical devices in the usa and europe (2015–20): a comparative analysis,

    U. J. Muehlematter, P. Daniore, and K. N. Vokinger, “Approval of artificial intelligence and machine learning-based medical devices in the usa and europe (2015–20): a comparative analysis,”The Lancet Digital Health, vol. 3, no. 3, pp. e195–e203, 2021

    2015

  55. [63]

    ARTIFICIAL INTELLIGENT MEDICAL DEVICE INNOVATION AND COOPERATION PLATFORM

    AIMD, “ARTIFICIAL INTELLIGENT MEDICAL DEVICE INNOVATION AND COOPERATION PLATFORM.” [Online]. Available: https://www.aimd.org.cn/

  56. [64]

    Artificial intelligence and machine learning (ai/ml)-enabled medical devices,

    U.S. Food and Drug Administration, “Artificial intelligence and machine learning (ai/ml)-enabled medical devices,” 2023, accessed: 2023-10-07. [On- line]. Available: https://www.fda.gov/medical-devices/software-medical-device-samd/ artificial-intelligence-and-machine-learning-...

    2023

  57. [65]

    The ethics of medical ai and the physician-patient relationship,

    S. Dalton-Brown, “The ethics of medical ai and the physician-patient relationship,”Cam- bridge Quarterly of Healthcare Ethics, vol. 29, no. 1, pp. 115–121, 2020

    2020

  58. [66]

    Cybersecurity features of digital medical devices: an analysis of fda product summaries,

    A. D. Stern, W. J. Gordon, A. B. Landman, and D. B. Kramer, “Cybersecurity features of digital medical devices: an analysis of fda product summaries,”BMJ open, vol. 9, no. 6, p. e025374, 2019

    2019

  59. [67]

    Performance of chatgpt on usmle: Po- tential for ai-assisted medical education using large language models,

    T. H. Kung, M. Cheatham, A. Medenilla, C. Sillos, L. De Leon, C. Elepaño, M. Madriaga, R. Aggabao, G. Diaz-Candido, J. Maningoet al., “Performance of chatgpt on usmle: Po- tential for ai-assisted medical education using large language models,”PLOS Digital Health, vol. 2, no. 2...

    2023

  60. [68]

    More than red tape: exploring complexity in medical device regulatory affairs,

    Y. Han, A. Ceross, and J. Bergmann, “More than red tape: exploring complexity in medical device regulatory affairs,”Frontiers in Medicine, vol. 11, p. 1415319, 2024. 28

    2024

Pith tools

Reviewed May 23, 2026 · model on record in the stance chip above.